Genitourinary Radiology: Page 48

3D subharmonic imaging better than harmonics for in vivo perfusion estimates
By Kate Madden Yee
Sunday, November 25 | 11:25 a.m.-11:35 a.m. | SSA21-05 | Room S405AB3D contrast-enhanced subharmonic imaging works well to estimate perfusion in vivo, according to a presentation to be given on Sunday morning by researchers at Thomas Jefferson University in Philadelphia.
November 6, 2012
Drug aids sexual function of prostate cancer patients after RT
By Cynthia E. Keen
Sildenafil citrate improves overall sexual function of prostate cancer patients who received radiation therapy (RT), according to trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the American Society for Radiation Oncology annual meeting.
November 5, 2012
Quantification replaces attenuation measurement for characterizing renal masses
By Eric Barnes
Friday, November 30 | 11:30 a.m.-11:40 a.m. | SST07-07 | Room E351Iodine quantification at dual-energy CT is a new diagnostic technique that can reduce the cost of additional tests in the characterization of renal masses, researchers from the University of Messina in Italy have found.
November 5, 2012
Contrast-induced nephropathy incidence is overestimated
By Eric Barnes
Tuesday, November 27 | 10:50 a.m.-11:00 a.m. | SSG08-03 | Room S102DCarefully performed studies suggest that the incidence and severity of contrast-induced nephropathy (CIN) after IV contrast injection for CT studies has been overestimated, according to researchers from the Mayo Clinic in Rochester, MN, who examined the incidence and severity of CIN in a meta-analysis.
November 5, 2012
ASTRO: SBRT for prostate cancer sustains cancer-free survival
By Cynthia E. Keen
Stereotactic body radiation therapy (SBRT) yields excellent cancer-free survival rates for intermediate-risk, organ-confined prostate cancer patients and results in few long-term rectal side effects, according to research presented at the American Society for Radiation Oncology (ASTRO) annual meeting.
October 31, 2012
ASTRO: Prostate screening has edge for high-risk patients
By Cynthia E. Keen
Annual prostate-specific antigen screening yields a slightly greater quality-adjusted life expectancy among patients who have a high risk of developing metastatic disease compared to unscreened patients, according to research presented on Tuesday at the American Society for Radiation Oncology (ASTRO) annual meeting.
October 30, 2012
ASTRO: Proton therapy outperforms IMRT for prostate cancer
By Cynthia E. Keen
Men undergoing proton beam therapy reported a higher quality of life immediately following treatment compared to men who received other forms of radiotherapy, according to research presented on Sunday at the American Society for Radiation Oncology (ASTRO) meeting in Boston.
October 28, 2012
NaF-PET/CT detects bone mets in prostate cancer patients
By Wayne Forrest
The use of PET/CT with a sodium fluoride (NaF) radiopharmaceutical produces high sensitivity, suggesting that the modality can be beneficial in detecting bone metastases caused by prostate cancer, according to a study published in the November issue of the American Journal of Roentgenology.
October 25, 2012
2012 10 25 15 14 34 684 2012 11 Ajr Mosavi B Thumb
10-year prostate cancer outcomes show rad therapy's benefit
By Cynthia E. Keen
Ten-year clinical outcomes for prostate cancer patients participating in a trial comparing postoperative radiotherapy with observation only show that patients who were irradiated had significantly improved biochemical progression-free survival and local control.
October 18, 2012
Contrast US finds higher-grade prostate cancers
By AuntMinnie.com staff writers
Contrast-enhanced ultrasound (CEUS) can detect high-grade prostate cancer better than conventional methods, according to an article published online in September in the Journal of Urology.
October 2, 2012
Risk markers found for erectile dysfunction after RT
By Cynthia E. Keen
Genetic markers associated with the development of erectile dysfunction in prostate cancer patients following radiation therapy (RT) have been identified, according to a study published online on September 27 in the International Journal of Radiation Oncology, Biology, Physics.
September 30, 2012
Molecular Insight launches phase II trial
By AuntMinnie.com staff writers
Radiopharmaceutical developer Molecular Insight Pharmaceuticals has begun a phase II clinical trial of its technetium-99m MIP-1404 prostate cancer molecular imaging agent.
September 26, 2012
Previous Page
Page 48 of 93
Next Page